Exogenous glucocorticoid dose impacts circulating microRNA expression in patients with adrenal insufficiency due to 21-hydroxylase deficiency

Read full text Summarise with VIRAT
Authors: Vipula Kolli, Jacob Trick, Annie Schulman, James Iben, Cameron J. Padilla, Tianwei Li, Fabio Rueda Faucz, Deborah P. Merke
Cited by: 0
References: 86

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Introduction: Patients with adrenal insufficiency due to 21-hydroxylase deficiency (21-OHD) are often exposed to supraphysiologic doses of glucocorticoids (GCs), which can augment metabolic dysfunction by altering glucose, lipid and protein metabolism. Exogenous GCs also fail to mimic the natural circadian rhythm of cortisol secretion. MicroRNAs (miRNAs) are important regulators of gene expression involved in various biological and pathological processes. GCs can regulate miRNAs and in turn miRNAs can modulate GC receptor (GR) activity influencing GR-mediated activity. In this pilot study, we examine the effects of exogenous GCs on circulating miRNA levels in patients with adrenal insufficiency due to classic 21-OHD. Patients/methods: /day hydrocortisone equivalents (HCe), respectively) were compared. Results: ≤ 0.03). Gene ontology enrichment and KEGG pathway analyses of sequencing results found that the differentially expressed miRNAs were involved in cell cycle progression and proliferation, insulin signaling, metabolic dysfunction, circadian rhythm, and GR signaling. Furthermore, MIENTURNET integrative pathway and network analyses of miRNAs identified 470 target genes, many of which play a role in insulin sensitivity, lipid metabolism, gluconeogenesis, oxidative stress and/or tumor metabolism. Conversely, no differences were observed in miRNA profiles between patients who were on short-acting compared to long-acting GCs. Conclusions: /day HCe impacts the expression of miRNAs that are known to be associated with GCs and their biological effects. The identification of a distinct circulating miRNA signature associated with supraphysiologic GC exposure in patients with CAH suggests that miRNAs could emerge as a valuable non-invasive biomarker for detecting GC excess and monitoring treatment.

Fields of Study & Subjects

Adrenal Hormones and Disorders Sexual Differentiation and Disorders MicroRNA in disease regulation

Publication details

Journal / source
Frontiers in Endocrinology
Volume
17
Pages
1784619–1784619
Publication date
31 March 2026
Language
EN